BioMarin Pharmaceutical Inc

31 Aug 2026, 21:01 UTC

BioMarin Pharmaceutical shares are lower in after-market trading amid cautious market sentiment influenced by hawkish comments from Fed Chair Kevin Warsh on inflation.

24 Aug 2026, 19:26 UTC

BioMarin Pharmaceutical announced its $275 million acquisition of Alesta Therapeutics. Shares are trading lower amid ongoing market volatility and geopolitical tensions.

21 Aug 2026, 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, despite earlier gains. Broader market volatility linked to rising crude oil prices may be influencing sentiment.

20 Aug 2026, 19:16 UTC

BioMarin Pharmaceutical shares are lower despite BMO initiating coverage with an Outperform rating and a price target of $98.

19 Aug 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

18 Aug 2026, 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, reflecting broader market declines amid profit-taking in technology and concerns over rising bond yields.

17 Aug 2026, 19:16 UTC

BioMarin shares are lower despite price target increases from Barclays and Piper Sandler, reflecting ongoing downward performance trends in recent sessions.

14 Aug 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from recent gains. Broader market sentiment is mixed amid a decline in U.S. retail sales.

13 Aug 2026, 22:36 UTC

Biomarin Pharmaceutical shares are higher in after-market hours, reflecting broader market positivity following the S&P 500's record close and easing inflation concerns.

12 Aug 2026, 23:01 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, with no specific news identified to explain the decline following five consecutive sessions of gains.

11 Aug 2026, 19:56 UTC

Biomarin Pharmaceutical Inc shares are higher, continuing a recent upward trend. Market focus is on upcoming economic indicators, including the Consumer Price Index report.

10 Aug 2026, 23:26 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading. Broader market sentiment remains cautious amid geopolitical tensions affecting investor confidence.

7 Aug 2026, 23:16 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. The broader market declined following recent labor market data affecting Federal Reserve rate hike expectations.

6 Aug 2026, 23:02 UTC

BioMarin Pharmaceutical reported second-quarter EPS of $1.20, surpassing estimates. Shares are trading higher in after-market hours following strong revenue growth and raised guidance.

5 Aug 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours amid routine trading, with no specific news identified to explain the movement.

4 Aug 2026, 19:46 UTC

Biomarin Pharmaceutical Inc shares are higher, supported by broader market strength amid a decline in crude oil prices, easing inflation concerns.

3 Aug 2026, 23:31 UTC

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

31 Jul 2026, 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today amid broader market declines, pressured by rising Treasury yields and increased crude oil prices.

30 Jul 2026, 19:08 UTC

Biomarin Pharmaceutical Inc shares are lower today, reflecting a decline since Wednesday's close amid broader economic uncertainty from rising jobless claims and weak GDP growth.

29 Jul 2026, 18:14 UTC

Biomarin Pharmaceutical Inc shares are lower today, with no specific news identified. Market sentiment remains mixed amid speculation on potential Federal Reserve rate hikes.

28 Jul 2026, 18:02 UTC

Biomarin Pharmaceutical is trading higher, benefiting from a strong Biotechnology sub-sector trend. Shares reached a peak earlier in the session amid favorable market conditions.

27 Jul 2026, 19:01 UTC

BioMarin Pharmaceutical announced a collaboration with the n-Lorem Foundation to develop a treatment for ReNU syndrome, boosting shares during Monday's session.

24 Jul 2026, 15:46 UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

22 Jul 2026, 23:31 UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

21 Jul 2026, 15:36 UTC

Biomarin Pharmaceutical Inc shares are higher as the Nasdaq gains, supported by strong technology stocks. The stock trades above its 20-day moving average.

20 Jul 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, remaining above their 20-day moving average amid broader market concerns over interest rates and economic growth.

16 Jul 2026, 19:06 UTC

Citi analyst raises price target on Biomarin Pharmaceutical to $76.00, maintaining a Buy rating. Shares are higher today amid positive sentiment and notable volatility.

15 Jul 2026, 23:21 UTC

Biomarin Pharmaceutical shares are higher in after-market trading, nearing the upper end of their one-month range amid broader market concerns over geopolitical tensions.

14 Jul 2026, 19:31 UTC

Biomarin Pharmaceutical shares are lower today, tracking declines in the Biotechnology sub-sector, continuing a downward trend since Monday's close.

13 Jul 2026, 19:46 UTC

BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO has been accepted by the FDA. Shares are lower today amid broader market sentiment.